Sirolimus. AY 22989, NSC 226080, NSC 606698, rapamycin, Rapamune.
D000818:Animals; D015507:Drugs, Investigational / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D005121:Extremities / Q000637:transplantation; D006084:Graft Rejection / Q000517:prevention & control*; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D007422:Intestines / Q000637:transplantation; D016381:Islets of Langerhans Transplantation / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology; D051379:Mice; D010215:Papio; D051381:Rats; D020123:Sirolimus / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016038:Skin Transplantation / Q000276:immunology
D015507:Drugs, Investigational; D007166:Immunosuppressive Agents; D020123:Sirolimus